Novartis partners with the Gates Foundation on one of the Holy Grails in gene therapy: a simple, in vivo approach to curing sickle cell disease

Having helped usher in a “new era” of sickle cell disease treatment with Adakveo, Novartis has set its sights on an even higher goal …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis part­ners with the Gates Foun­da­tion on one of the Holy Grails in gene ther­a­py: a sim­ple, in vi­vo ap­proach to cur­ing sick­le cell dis­ease